InterVenn Investigator Initiated Research Program in Glycoproteomics

DAWN™ IO | Melanoma Test Is Now Available

Now, before starting therapy, you can identify metastatic melanoma patients who are “Likely” or “Not Likely to Benefit” from certain immunotherapies.
Learn more

DAWN™ IO | Melanoma is a laboratory developed test to assess whether a patient is likely to benefit from immune checkpoint inhibitor therapy, specifically nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) or pembrolizumab (Keytruda®) monotherapy.

INTERVENN’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The DAWN IO Melanoma test was developed, and its performance characteristics were determined by INTERVENN. The DAWN IO Melanoma test has not been cleared or approved by the U.S. Food and Drug Administration. INTERVENN’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The DAWN IO Melanoma test is intended for clinical purposes.

Product Pipeline

Indication Clinical Application Phase
Proof of Concept Classifier Validation LDT Validation Commercially Available
Metastatic MelanomaImmuno-Therapy Response Prediction - DAWN IO
Ovarian CancerPelvic Mass Triaging - GLORI
Non Small Cell Lung Carcinoma (NSCLC)Immuno-Therapy Response Prediction - DAWN IO
Advanced AdenomaPre-malignant Detection, Cancer Prevention
Colorectal CancerEarly Cancer Detection, Colonoscopy Triaging
Prostate CancerDifferentiation Between Indolent and Aggressive Variants
Non-Alcoholic SteatoHepatitis (NASH)Early Detection, and Clinical Decision
Hepatocellular Carcinoma (HCC)Early Detection, and Clinical Decision
Nasopharyngeal CarcinomaEarly Detection, and Clinical Decision
Renal Cell CarcinomaDifferentiation Between Indolent and Aggresive Variants
Pancreas CarcinomaEarly Detection
Non Small Cell Lung Carcinoma (NSCLC)Early Detection

Other Pipeline Products

Our goal has always been to help patients and physicians by providing products that provide unprecedented insight and benefit. We will continue to advance this cause by introducing new tests and applications and leveraging our analytical platform.

References

  1. G Xu, D Serie, M Wong, L Shen, P Buckley, P Ramachandran, R Rice, C Lebrilla, K Lindpaintner, H Xu; Targeted Serum Glycoprotein Profiling and Quantification by LC-MS/MS for Detection of Ovarian Cancer. Citation ID 304716, 2020 Jun 4th, Proceedings of the 68th ASMS Conference on Mass Spectrometry and Allied Topics Online Meeting, June 1-12, 2020. https://www.abstracts.asms.org/pages/dashboard.html#/conference/291/toc/291/details
  2. R E Bristow, A Smith, Z Zhang, D W Chan, G Crutcher, E T Fung, D G Munroe; Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic Oncology. 2013 Feb;128(2):252-9. doi: 10.1016/j.ygyno.2012.11.022
  3. G Xu, R Rice, H Huang, K Lindpaintner, JM Prendergast, K Normington, D Frederick, GM Boland, D Serie. Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 387. https://www.abstracts.asms.org/pages/dashboard.html#/conference/291/toc/291/details
  4. Data on file. Pending acceptance of publications for NSCLC and malignant melanoma.